|
Fig. S5 P-TEFb is required for NSpt5’s in vivo effects. (A-D) The morphological phenotypes of CDK9 morpholino-injected (B), NSpt5-expressing (C), or CDK9 morpholino-injected and NSpt5-expressing (D) embryos. (E-F) flavopiridol (FP) treated (E) embryos as compared to FP treated and NSpt5-expressing embryos (F). (G-I) The morphological phenotypes of CDK9 morpholino-injected (G), NSpt5-expressing (H), or CDK9 morpholino-injected and NSpt5-expressing (I) embryos at later developmental stages. These studies show that impairment of CDK9 activity partially suppressed the dorsalization phenotype of NSpt5-expressing embryos. (J-K) Quantitative RT-PCR analyses show that both CDK9 MO and FP treatment decreases hsp70 transcripts induced by NSpt5. Abbreviations, h, head; t, tail; y, yolk.